中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 36 Issue 12
Dec.  2020
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2020  >  36(12): 2782-2782

Mechanism of action of magnolol in the treatment of acute lung injury in a rat model of severe acute pancreatitis

DOI: 10.3969/j.issn.1001-5256.2020.12.028

  • Department of Infectious Diseases,Beijing Friendship Hospital,Capital Medical University

  • Graduate School of Capital Medical University

Research funding:

 

  • Received Date: 2020-04-29
  • Published Date: 2020-12-20
    Abstract

  • Objective To investigate the therapeutic effect of magnolol on severe acute pancreatitis( SAP) with acute lung injury from the aspect of the functional block of intestinal lymphatic circulation by magnolol. Methods A total of 30 healthy male Sprague-Dawley rats were randomly divided into sham-operation group,SAP group,and magnolol treatment group,with 10 rats in each group. The rats in the sham-operation group were given laparotomy to flip the pancreas,followed by abdominal closure; the rats in the SAP group were given retrograde pancreaticobiliary injection of 3. 75% sodium taurocholate to establish a rat model of SAP; the rats in the magnolol treatment group were given injection of magnolol 0. 2 mg/kg via the penile vein at 15 minutes before modeling. The three groups were compared in terms of pathological changes of the lung and the intestine,pathological score,the levels of D-lactic acid( DLA),diamine oxidase( DAO),high-mobility group box 1( HMGB1),receptor for advanced glycation end products( RAGE),interleukin-1β( IL-1β),interleukin-8( IL-8),interleukin-10( IL-10),and tumor necrosis factor-α( TNFα) in serum,lymphatic fluid,and tissue homogenate of the lung and the intestine,and the level of Toll-like receptor 4( TLR4) in lymphatic fluid. An analysis of variance was used for comparison of normally distributed continuous data between multiple groups,and the Kruskal-Wallis H test was used for comparison of non-normally distributed continuous data between multiple groups. Results The SAP group had congestion,edema,inflammatory cell infiltration,and bleeding in the pulmonary interstitium,and the magnolol treatment group had mild bleeding and inflammatory cell infiltration in the pulmonary interstitium,with a significantly lower degree than the SAP group. Compared with the SAP group,the magnolol treatment group had significantly lower serum levels of DAO,DLA,IL-1β,IL-8,TNFα,HMGB1,and RAGE( all P < 0. 05) and significantly lower levels of DAO,DLA,IL-1β,IL-8,TNFα,HMGB1,and RAGE in the lymphatic fluid( all P < 0. 05). Compared with the SAP group,the sham-operation group had sig-nificantly lower serum levels of DAO,DLA,IL-1β,IL-8,TNFα,HMGB1,and RAGE( all P < 0. 05) and significantly lower levels of DAO,DLA,IL-1β,IL-8,TNFα,HMGB1,and RAGE in the lymphatic fluid( all P < 0. 05). Compared with the SAP group,the magnolol treatment group had significantly lower levels of IL-1β,IL-8,TNFα,HMGB1,and RAGE in lung tissue( all P < 0. 05) and intestinal tissue( all P < 0. 05). Compared with the SAP group,the sham-operation group had significantly lower levels of IL-1β,IL-8,TNFα,HMGB1,and RAGE in lung tissue( all P < 0. 05) and intestinal tissue( all P < 0. 05). Compared with the SAP group,the magnolol treatment group and sham-operation group had a significant reduction in the protein expression of TLR4 in the lymphatic fluid( all P < 0. 05). Conclusion Magnolol can improve intestinal barrier function and alleviate lung injury in SAP by blocking intestinal lymphatic circulation,reducing the levels of inflammatory factors,and inhibiting the HMGB1-TLR4/NF-κB signal transduction pathway.

     

    • FullText(HTML)
    • References(21)
  • [1] RENNER IG,SAVAGE WT 3rd,PANTOJA JL,et al. Death due to acute pancreatitis. A retrospective analysis of 405 autopsy cases[J]. Dig Dis Sci,1985,30(10):1005-1018.
    [2] STEER ML. Relationship between pancreatitis and lung diseases[J]. Respir Physiol,2001,128(1):13-16.
    [3] WANG D,LI Y,FAN LQ,et al. Expression and significance of NF-kB,IL-6 and TNF-αin liver injury interfered by thoracic duct drainage of severe acute pancreatitis[J]. J Hebei Med Univ,2010,31(8):905-908.(in Chinese)王冬，李勇，范立侨，等．大鼠重症急性胰腺炎肝损伤经胸导管引流干预时NF-κB、IL-6、TNF-α的表达及意义[J]．河北医科大学学报，2010,31(8):905-908.
    [4] WANG HM,ZHANG SW. Research progress of magnolol pharmacology[J]. Beijing J Tradit Chin Med,2009,28(7):562-565.(in Chinese)王海曼，张淑文．厚朴酚药理作用的研究进展[J]．北京中医药，2009,28(7):562-565.
    [5] MIAO B,ZHANG SW,WANG H,et al. Magnolol pretreatment prevents sepsis-induced intestinal dysmotility by maintaining functional interstitial cells of Cajal[J]. J Capit Med Univ,2013,34(2):163-170.(in Chinese)苗彬，张淑文，王红，等．Cajal细胞在脓毒症所致胃肠动力障碍中的形态改变及厚朴酚干预的实验研究[J]．首都医科大学学报，2013,34(2):163-170.
    [6] ZHANG YL,YUAN WH,XU M,et al. The role of cold-inducible RNA-Binding protein(CIRP)in early liver damage of severe acute pancreatitis with secondary infection[J]. Chin J Dig,2011,31(5):330-334.(in Chinese)．张尤历，袁伟红，徐岷，等．重症急性胰腺炎继发感染早期肝损伤时髓样细胞表达激发受体-1的诊断价值[J]．中华消化杂志，2011,31(5):330-334.
    [7] FENG SY. Rhubarb to prevent gastrointestinal failure[J]. Chin J Integr Trad West Med,2000,20(10):795-797.(in Chinese)冯顺友．大黄防治胃肠功能衰竭[J]．中国中西医结合杂志，2000,20(10):795-797.
    [8] YE ML,PENG Y. Research advance in the mechanism of intestinal motility disorders in patients with severe acute pancreatitis[J]. Med Recapitul,2016,22(20):4039-4042.(in Chinese)．叶美玲，彭燕．急性重症胰腺炎肠道动力障碍机制的研究进展[J]．医学综述，2016,22(20):4039-4042.
    [9] ZHANG Y,TANG F. Advance in latest studies on pharmacological effects of magnolol[J]. China J Chin Mater Med,2012,37(23):3526-3530.(in Chinese)张勇，唐方．厚朴酚药理作用的最新研究进展[J]．中国中药杂志，2012,37(23):3526-3530.
    [10] QIN C,DAI X,YANG XQ,et al. Intervention effect of honokiol on inflammatory response in lung tissue of asthma mice and its mechanism[J]. J Jilin Univ(Med Edit),2020,46(2):214-220,431.(in Chinese)秦超，戴曦，杨小琼，等．和厚朴酚对哮喘小鼠肺组织炎症反应的干预作用及其机制[J]．吉林大学学报(医学版)，2020,46(2):214-220,431.
    [11] DUAN JQ,LIN Y,ZHAO QF,et al. The protective effect and mechanism of magnolol on acute lung injury in sepsis rat model[J]. Chin J Gerontol,2018,38(11):2745-2747.(in Chinese)段金旗，林艳，赵芹芳，等．厚朴酚对脓毒症大鼠模型急性肺损伤的保护作用及机制[J]．中国老年学杂志，2018,38(11):2745-2747.
    [12] SEELY AJ,NAUD JF,CAMPISI G,et al. Alteration of chemoattractant receptor expression regulates human neutrophil chemotaxis in vivo[J]. Ann Surg,2002,235(4):550-559.
    [13] PASZKOWSKI AS,RAU B,MAYER JM,et al. Therapeutic application of caspase 1/interleukin-1beta-converting enzyme inhibitor decreases the death rate in severe acute experimental pancreatitis[J]. Ann Surg,2002,235(1):68-76.
    [14] LIU ZY,FEI H,LIU J,et al. The role of daphnetin pretreatment on histopathologic changes and serum IL-6,IL-10 levels in a-cute pancreatitis rats[J]. Chin J Microcirc,2016,26(2):1-4,85.(in Chinese)刘志勇，费浩，刘娇，等．瑞香素预处理对急性胰腺炎大鼠组织病理变化和白细胞介素-6、白细胞介素-10水平的作用[J]．微循环学杂志，2016,26(2):1-4,85.
    [15] SONG RB,MA JT. Regulation of IL-10 on inflammation-related cytokines in severe pancreatitis in rats[J]. Hebei Med J,2009,31(12):1451-1452.(in Chinese)宋润波，马建亭．IL-10对大鼠重症胰腺炎炎症相关细胞因子的调节作用[J]．河北医药，2009,31(12):1451-1452.
    [16] LI L,YU J,MU R,et al. Clinical effect of electroacupuncture on lung injury patients caused by severe acute pancreatitis[J]. Evid Based Complement Alternat Med,2017,2017:3162851.
    [17] ZHANG G,LIU XB,HU WM. Relationship between TNFαgene expression and lung injury in the lungs of acute pancreatitis rats[J]. World Chin J Dig,2000,8(2):142.(in Chinese)．张刚，刘续宝，胡伟明．急性胰腺炎大鼠肺内TNFα基因表达与肺损伤的关系[J]．世界华人消化杂志，2000,8(2):142.
    [18] LU HH,SHI Z,LIU B,et al. Effects of TNFα，IL-1,IL-6 in acute pancreatitis-associated acute lung injury[J].Chongqing Med,2007,36(18):1818-1819.(in Chinese)陆海华，史忠，刘波，等．急性胰腺炎相关性肺损伤患者早期血清TNFα、IL-1、IL-6的变化及其临床意义[J]．重庆医学，2007,36(18):1818-1819.
    [19] WANG M,WANG B. HMGB1 of sepsis biomarkers and drug target of traditional Chinese medicine[J]. Jilin J Tradit Chin Med,2018,38(4):494-496.(in Chinese)王淼，王兵．HMGB1作为脓毒症生物标记物与中药药物靶点的研究进展[J]．吉林中医药，2018,38(4):494-496.
    [20] WANG J,HUANG Z,WEI W,et al. The expression of HMGB1 in lung injury and the effect of ulinastatin on rats with severe acute pancreatitis[J]. Med J West China,2018,30(2):174-177,181.(in Chinese)．王静，黄忠，魏尉，等．HMGB1在重症急性胰腺炎大鼠肺损伤中的表达及乌司他丁的干预效应[J]．西部医学，2018,30(2):174-177,181.
    [21] SIMS GP,ROWE DC,RIETDIJK ST,et al. HMGB1 and RAGE in inflammation and cancer[J]. Annu Rev Immunol,2010,28:367-388.
    • Relative Articles

  • Relative Articles

    [1]Tao WANG, Fenghui LI, Jing LIANG, Huiling XIANG, Fang LIU, Hongmin LYU, Baoxin QIAN, Jiajun TIAN. Clinical effect of direct-acting antiviral agents in treatment of chronic hepatitis C patients with thrombocytopenia[J]. Journal of Clinical Hepatology, 2022, 38(1): 91-96. doi: 10.3969/j.issn.1001-5256.2022.01.014
    [2]Hongyu CHEN, Qian KANG, Hao LUO, Ning TAN, Jiali PAN, Ran CHENG, Yifan HAN, Yuqing YANG, Dan LIU, Hongli XI, Min YU, Xiaoyuan XU. Virological response to direct-acting antiviral therapy and changes in liver fibrosis indices in chronic hepatitis C patients with different alanine aminotransferase and aspartate aminotransferase levels in a real-world setting[J]. Journal of Clinical Hepatology, 2021, 37(2): 314-317. doi: 10.3969/j.issn.1001-5256.2021.02.014
    [3]Qian ZHU, Mingyuan ZHANG, Junqi NIU. Advances in direct-acting antiviral therapy for liver transplant recipients with HCV-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(10): 2444-2447. doi: 10.3969/j.issn.1001-5256.2021.10.039
    [4]CHEN HongYu, XU XiaoYuan. Drug resistance of direct-acting antivirals in genotype 2/3 hepatitis C virus[J]. Journal of Clinical Hepatology, 2020, 36(11): 2553-2556. doi: 10.3969/j.issn.1001-5256.2020.11.035
    [5]LIU YuWei, JIN JingLan, REN TianYi, GAO XiuZhu, LI Jie, ZHU Qing, NIU JunQi. Effect of direct-acting antiviral on the recurrence hepatitis C virus-related hepatocellular carcinoma after curative treatment: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(12): 2714-2719. doi: 10.3969/j.issn.1001-5256.2020.12.015
    [6]Ning HuiBin, Liu JunPing, Jin HuiMing, Li Kuan, Xiao ErHui, Shang Jia. Direct-acting antiviral durgs for hepatitis C in children: A case report[J]. Journal of Clinical Hepatology, 2019, 35(1): 164-165. doi: 10.3969/j.issn.1001-5256.2019.01.032
    [7]Zhang JieBing, Guo HongHua. Research advances in hepatitis B cirrhosis with renal injury and the application of antiviral drugs[J]. Journal of Clinical Hepatology, 2019, 35(1): 191-196. doi: 10.3969/j.issn.1001-5256.2019.01.042
    [8]Zhang Xi, Li YongGuo. Current status of the application of direct-acting antiviral agents in treatment of chronic hepatitis C and existing problems[J]. Journal of Clinical Hepatology, 2018, 34(4): 853-857. doi: 10.3969/j.issn.1001-5256.2018.04.034
    [9]Wang Cheng, Liao JiaJie. Treatment of HBV/HCV co-infected patients in DAA era[J]. Journal of Clinical Hepatology, 2017, 33(6): 1011-1016. doi: 10.3969/j.issn.1001-5256.2017.06.001
    [10]Wu Dan, Li ZhiWei. Accurate clinical examination guarantees the whole management process of hepatitis C patients in the era of direct-acting antiviral agents[J]. Journal of Clinical Hepatology, 2017, 33(6): 1058-1062. doi: 10.3969/j.issn.1001-5256.2017.06.008
    [11]Chen XinYue, Liu YaLi, Ren Shan. Value of direct-acting antivirals combined with PR regimen (PEG-IFN combined with ribavirin) in the new era of antiviral therapy for hepatitis C[J]. Journal of Clinical Hepatology, 2017, 33(6): 1063-1066. doi: 10.3969/j.issn.1001-5256.2017.06.009
    [12]Ceng Qun, Jie ShengHua. Research advances in antiviral drugs and their treatment regimens in chronic hepatitis C[J]. Journal of Clinical Hepatology, 2017, 33(11): 2200-2204. doi: 10.3969/j.issn.1001-5256.2017.11.033
    [13]Bian DanDan, Zheng SuJun. Influencing factors for the therapeutic effect of direct-acting antiviral agents in hepatitis C[J]. Journal of Clinical Hepatology, 2017, 33(11): 2205-2208. doi: 10.3969/j.issn.1001-5256.2017.11.034
    [14]Wen XiaoYu, Niu JunQi. Mechanism of action of direct-acting antiviral agents in treatment of chronic hepatitis C[J]. Journal of Clinical Hepatology, 2016, 32(9): 1699-1705. doi: 10.3969/j.issn.1001-5256.2016.09.013
    [15]Tu YanYun, Chen HaiYan, Liu XuDong. Research progress in antiviral therapy for decompensated hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(3): 460-464. doi: 10.3969/j.issn.1001-5256.2015.03.036
    [16]Li Qiang, Huang YuXian, Chen Liang. Present situation of antiviral therapies for HCV-related cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(11): 1813-1816. doi: 10.3969/j.issn.1001-5256.2015.11.011
    [17]Ren Shan, Chen XinYue. Current research on hepatitis C virus resistance to direct-acting antiviral agents[J]. Journal of Clinical Hepatology, 2015, 31(11): 1807-1812. doi: 10.3969/j.issn.1001-5256.2015.11.010
    [18]Zhang Jing, Liu XueMin, Liu ZhengWen, Lu: Yi. Application of direct-acting antiviral agents in perioperative period of liver transplantation for patients with hepatitis C[J]. Journal of Clinical Hepatology, 2015, 31(12): 2084-2087. doi: 10.3969/j.issn.1001-5256.2015.12.023
    [19]Li YuYuan. Antiviral therapy for hepatitis B /C virus-related cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(7): 596-600. doi: 10.3969/j.issn.1001-5256.2014.07.005
    [20]Wei Xin, Xie YuMei, Chen Lin, Pan Lei, Hao ChunQiu, Wang JiuPing, Bai XueFan, Jia ZhanSheng. Antiviral therapy with pegylated interferon alpha-2a plus ribavirin in patients with HCV related cirrhosis and to establish the grading for standard therapy[J]. Journal of Clinical Hepatology, 2011, 27(1): 89-92.
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(2)

    1. 李鑫磊. 骨骼肌损伤修复中的前列腺素E2. 中国组织工程研究. 2025(24): 5187-5194 .
    2. 张宣，张鹏程，李玉茹. 麻桂温经汤对中老年肩周炎患者关节功能及疼痛介质水平的影响. 长春中医药大学学报. 2022(11): 1242-1245 .

    Other cited types(0)

  • Created with Highcharts 5.0.7Amount of accessChart context menuAbstract Views, HTML Views, PDF Downloads StatisticsAbstract ViewsHTML ViewsPDF Downloads2024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-032025-0405101520
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 32.3 %FULLTEXT: 32.3 %META: 61.2 %META: 61.2 %PDF: 6.5 %PDF: 6.5 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 5.1 %其他: 5.1 %其他: 0.6 %其他: 0.6 %China: 0.9 %China: 0.9 %India: 0.6 %India: 0.6 %Rochester: 0.1 %Rochester: 0.1 %United States: 0.9 %United States: 0.9 %[]: 0.4 %[]: 0.4 %上海: 2.2 %上海: 2.2 %东京都: 0.2 %东京都: 0.2 %中卫: 0.1 %中卫: 0.1 %九江: 0.1 %九江: 0.1 %北京: 3.4 %北京: 3.4 %南京: 0.4 %南京: 0.4 %南充: 0.2 %南充: 0.2 %南宁: 0.1 %南宁: 0.1 %南阳: 0.1 %南阳: 0.1 %合肥: 0.2 %合肥: 0.2 %吉林: 0.5 %吉林: 0.5 %大连: 0.2 %大连: 0.2 %天津: 1.0 %天津: 1.0 %宁波: 0.1 %宁波: 0.1 %定西: 0.1 %定西: 0.1 %常州: 0.2 %常州: 0.2 %常德: 0.1 %常德: 0.1 %广州: 0.6 %广州: 0.6 %张家口: 5.6 %张家口: 5.6 %徐州: 0.1 %徐州: 0.1 %昆明: 0.2 %昆明: 0.2 %晋城: 0.1 %晋城: 0.1 %杭州: 0.6 %杭州: 0.6 %武汉: 0.2 %武汉: 0.2 %永州: 0.1 %永州: 0.1 %河池: 0.1 %河池: 0.1 %泰州: 0.1 %泰州: 0.1 %洛阳: 0.1 %洛阳: 0.1 %海得拉巴: 0.4 %海得拉巴: 0.4 %海西蒙古族藏族自治州: 0.1 %海西蒙古族藏族自治州: 0.1 %深圳: 0.2 %深圳: 0.2 %湖州: 0.1 %湖州: 0.1 %湘潭: 0.1 %湘潭: 0.1 %湛江: 0.4 %湛江: 0.4 %漯河: 0.1 %漯河: 0.1 %班加罗尔: 0.1 %班加罗尔: 0.1 %石家庄: 4.4 %石家庄: 4.4 %福州: 0.4 %福州: 0.4 %绥化: 0.1 %绥化: 0.1 %绵阳: 0.1 %绵阳: 0.1 %美国: 0.1 %美国: 0.1 %美国伊利诺斯西芝加哥: 0.1 %美国伊利诺斯西芝加哥: 0.1 %芒廷维尤: 39.0 %芒廷维尤: 39.0 %芝加哥: 0.2 %芝加哥: 0.2 %莫斯科: 1.5 %莫斯科: 1.5 %衢州: 0.1 %衢州: 0.1 %西宁: 18.8 %西宁: 18.8 %西安: 0.2 %西安: 0.2 %贵阳: 0.2 %贵阳: 0.2 %赤峰: 0.5 %赤峰: 0.5 %运城: 1.7 %运城: 1.7 %郑州: 0.5 %郑州: 0.5 %重庆: 0.2 %重庆: 0.2 %长春: 1.6 %长春: 1.6 %长沙: 1.2 %长沙: 1.2 %阿什本: 0.4 %阿什本: 0.4 %韶关: 0.1 %韶关: 0.1 %黄冈: 0.2 %黄冈: 0.2 %其他其他ChinaIndiaRochesterUnited States[]上海东京都中卫九江北京南京南充南宁南阳合肥吉林大连天津宁波定西常州常德广州张家口徐州昆明晋城杭州武汉永州河池泰州洛阳海得拉巴海西蒙古族藏族自治州深圳湖州湘潭湛江漯河班加罗尔石家庄福州绥化绵阳美国美国伊利诺斯西芝加哥芒廷维尤芝加哥莫斯科衢州西宁西安贵阳赤峰运城郑州重庆长春长沙阿什本韶关黄冈

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (4011) PDF downloads(67) Cited by(2)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[1659]YesterdayPV[2864]TodayIP[106]TodayPV[178]Online[14]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return